TP53 and myelodysplastic syndrome: However, the combination strategy did not meet the primary endpoint in a phase 3 clinical trial for patients with TP53-mutated MDS, although the CR rate tended to be superior in the combination group compared to the azacitidine monotherapy group (33.3 vs. 22.4%) [156].